Significance of Evaluating Tumor Markers in the Oncological Criteria for Resectability in Hepatocellular Carcinoma.
[BACKGROUND] The Japan Liver Cancer Association and the Japanese Society of Hepato-Biliary-Pancreatic Surgery proposed oncological resectability criteria for hepatocellular carcinoma (HCC), classifyin
- p-value p < 0.001
- p-value p = 0.008
APA
Miura Y, Ashida R, et al. (2026). Significance of Evaluating Tumor Markers in the Oncological Criteria for Resectability in Hepatocellular Carcinoma.. Hepatology research : the official journal of the Japan Society of Hepatology, 56(4), 550-561. https://doi.org/10.1111/hepr.70096
MLA
Miura Y, et al.. "Significance of Evaluating Tumor Markers in the Oncological Criteria for Resectability in Hepatocellular Carcinoma.." Hepatology research : the official journal of the Japan Society of Hepatology, vol. 56, no. 4, 2026, pp. 550-561.
PMID
41405969
Abstract
[BACKGROUND] The Japan Liver Cancer Association and the Japanese Society of Hepato-Biliary-Pancreatic Surgery proposed oncological resectability criteria for hepatocellular carcinoma (HCC), classifying tumors as R, BR1, or BR2. However, serum tumor markers, such as alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin (DCP), despite their prognostic value, were not incorporated.
[METHODS] We retrospectively analyzed 803 patients undergoing curative liver resection for HCC. Significant tumor marker elevation (TM-high) was defined as AFP > 500 ng/mL or DCP > 1000 mAU/mL. Overall survival (OS) and relapse-free survival (RFS) were compared according to resectability status and tumor marker levels.
[RESULTS] TM-high status was observed in 171 patients with R (32.3%), 75 patients with BR1 (27.5%), and 46 patients with BR2 (70.1%). In the R group, TM-high patients had significantly worse outcomes than non-TM-high patients (median survival time [MST], RFS: 26.9 vs. 55.9 months, and p < 0.001; OS: 120.7 vs. 160.8 months and p = 0.008). No significant difference in the OS was observed between R/TM-high and BR1/non-TM-high patients (120.7 vs. 103.1 months and p = 0.159) or BR1/TM-high and BR2/non-TM-high patients (58.7 vs. 58.5 months and p = 0.657). Multivariate analyses confirmed that a TM-high status was an independent predictor for both the RFS (HR 1.36 and p < 0.003) and OS (HR 1.50 and p < 0.001).
[CONCLUSION] AFP and DCP provide independent prognostic information beyond the oncological resectability criteria. Incorporating tumor markers may refine risk stratification and optimize multidisciplinary treatment strategies for HCC.
[METHODS] We retrospectively analyzed 803 patients undergoing curative liver resection for HCC. Significant tumor marker elevation (TM-high) was defined as AFP > 500 ng/mL or DCP > 1000 mAU/mL. Overall survival (OS) and relapse-free survival (RFS) were compared according to resectability status and tumor marker levels.
[RESULTS] TM-high status was observed in 171 patients with R (32.3%), 75 patients with BR1 (27.5%), and 46 patients with BR2 (70.1%). In the R group, TM-high patients had significantly worse outcomes than non-TM-high patients (median survival time [MST], RFS: 26.9 vs. 55.9 months, and p < 0.001; OS: 120.7 vs. 160.8 months and p = 0.008). No significant difference in the OS was observed between R/TM-high and BR1/non-TM-high patients (120.7 vs. 103.1 months and p = 0.159) or BR1/TM-high and BR2/non-TM-high patients (58.7 vs. 58.5 months and p = 0.657). Multivariate analyses confirmed that a TM-high status was an independent predictor for both the RFS (HR 1.36 and p < 0.003) and OS (HR 1.50 and p < 0.001).
[CONCLUSION] AFP and DCP provide independent prognostic information beyond the oncological resectability criteria. Incorporating tumor markers may refine risk stratification and optimize multidisciplinary treatment strategies for HCC.
같은 제1저자의 인용 많은 논문 (5)
- Waist-to-Height Ratio as a Predictor Complementary to BMI for Postoperative Pancreatic Fistula After Pancreatoduodenectomy for Periampullary Tumors.
- Concurrent Chemoradiotherapy with Daily Low-Dose Carboplatin in Older Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer: Clinical Outcomes and Prognostic Significance of Systemic Inflammation Markers.
- ASO Author Reflections: Genomic Features of Familial and Sporadic Pancreatic Cancer.
- Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features.
- A computational model of inflammation reveals crosstalk among energy metabolism, oxidative stress, insulin, and cytokines in hepatocytes during early MASLD progression.